Drugs / CB-PRP
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06661382 | Jan 2023 → Nov 2024 overdue | vulvar lichen sclerosus | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04636853 | Dec 2020 → Dec 2021 | dry age related macular degeneration, retinitis pigmentosa | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CB-PRP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06661382 ↗ |
| Known as | umbilical cord blood platelet-rich plasma | “A subretinal injection of umbilical cord blood platelet-rich plasma (CB-PRP) will be performed only in one eye, the other eye will be considered as a control group.” NCT04636853 ↗ |
| Modality | Protein / enzyme biologic | “Biological: Subretinal injection of umbilical cord blood platelet-rich plasma (CB-PRP)” NCT04636853 ↗ |
| Route | Other | “A subretinal injection of umbilical cord blood platelet-rich plasma (CB-PRP) will be performed only in one eye” NCT04636853 ↗ |